COVID-19 Project
See: https://tinyurl.com/2tby43u3
This study shall investigate the potential use of stable nanoscopic copper(I) complexes, e.g., neocuproine copper(I), bathocuproine disulfonic acid copper(I), and other biometallic compounds, e.g., zinc USP, silver, hemin and hematin, toward development of novel nanoscopic formulations for use as anti-viral nasal spray/gargle therapy for treatment of nasal-facilitated infection pathways, via product formulation submitted to USFDA trade named, “Coronacide®”. These substances are designed to function as anti-viral antagonists carried in (GRAS) solutions, e.g., melarsoprol or eflornithine, which have been found to be effective in treatment of other vectors, e.g., trypanasomiasis (via hydroxychloroquine). Preliminary findings indicate that the use of stable copper(I) complexes, comprising a (I) ion complexed by a poly[1]dentate ligand favoring the +1 oxidation state for copper, along with stable copper(I) complexes in a lipid[1]based nano-scale delivery modulus (nanocapsules), in a pharmaceutically acceptable carrier or diluent solution, could be used as an anti-viral, lipid-modulating antagonist against the COVID-19 organism as gargle or sprayed directly into the nasal cavity where this organism thrives, resulting in instantaneous necrotic onset to the targeted vector (COVID-19) with time-released efficacy of 12-16 hours. Formulation referred to as “CIS-1” (Coronacide® Intranasal Spray). Condition or disease Intervention/treatment COVID-19SARS-CoV 2 Drug: Coronacide® Neocuproine Copper(I), Bathocuproine Disulfonic Acid Copper(I).